NASDAQ · Biotechnology

BBOT (BBOT) Stock

$8.09 -4.82% NASDAQ: BBOT Healthcare

Valuation

MetricValue
Price$8.09
Market Cap$648.07M
P/E Ratio-3.62
P/B Ratio1.67
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$14.87
52-Week Low$7.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-62.21%
ROA-37.19%
ROCE-35.52%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio12.14

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$0$0$-65.0M$-81.0M$-146.0M
Net Profit$0$0$-65.0M$-74.0M$-134.0M
EPS$0.00$0.00$-3.16$0.46$-4.30
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$0$194.0M$448.0M
Total Liabilities$0$0$0$6.0M$37.0M
Cash$0$0$0$2.0M$374.0M
Borrowings$0$0$0$0$3.0M

Latest News

JPMorgan Initiates BridgeBio Oncology Therapeutics at Overweight MT Newswires · Jul 8, 2026 Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? Insider Monkey · Jun 30, 2026 Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Motley Fool · May 17, 2026 Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally Motley Fool · May 17, 2026 Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More Motley Fool · May 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$0$0$-52.0M$-1.0M$-114.0M
Investing Cash Flow$0$0$0$-184.0M$73.0M
Financing Cash Flow$0$0$0$-1.0M$-12.0M
Net Cash Flow$0$0$0$2.0M$343.0M
Free Cash Flow$0$0$-52.0M$-1.0M$-114.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-2.20
FCF Yield-27.83%
Quick Ratio6.16
Interest Coverage—
Return 1Y-18.43%
Return 3Y—
Return 5Y—

Ownership

Insiders Held27.11%
Institutions Held68.90%
Institutions Float Held94.53%
Institutional HolderSharesReport Date
Cormorant Asset Management, LP17,878,5942026-03-31
Deerfield Management Company, L.P4,885,4462026-03-31
Omega Fund Management, Llc3,289,6612026-03-31
Alphabet Inc.2,823,1262026-03-31
EcoR1 Capital, LLC2,823,1262026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANAB $53.61 -1.00% -127.70 $2.31B 0.00%
KOD $41.58 -2.16% -8.11 $2.60B 0.00%
MNMDMind Medicine (MindMed) Inc. $20.69 +0.44% -18.83 $1.56B 0.00%
NRIX $24.11 -0.17% -6.41 $2.50B 0.00%
OCS $11.29 +2.08% -14.61 $645.16M 0.00%

About BBOT

BBOT is led by CEO Eli Wallace, publicly traded since 2025.

BBOT stock trades at $8.09 with a market capitalization of $648.07M. The stock is valued at a price-to-earnings (P/E) ratio of -3.62, price-to-book of 1.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.00 and $14.87, and currently trades 45.6% below its 52-week high.

On profitability, BBOT generates a return on equity (ROE) of -62.21%, return on capital employed of -35.52%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides